Supplementary table 1. Health outcomes, costs and cost-effectiveness of different HIV testing approaches in four country-based cases (per 1,000,000 pregnant women)

Incremental cost-effectiveness ratio (US\$)

-				Health Outco	mes				Costs (US\$ thous	ands)		based on	PMTCT cost ²
Country-based case (HIV prevalence among pregnant women)	Approach	MTCT Rate	Number of HIV+ women identified	Number of new paediatric infections	Number paediatric infections averted	Quality- adjusted life years (QALYs) gained	HIV testing (test kit + services)	PMTCT (HIV test, ARVs, and health services)	Paediatric treatment (20 years)	Total cost (PMTCT including HIV testing + paediatric treatment)	Cost saved ¹	cost per infection averted	cost per QALY gained
	Highly focused	18%	89,710	30,019	24,824	496,475	1,527	28,446	70,322	98,768	107,106		
Namibia (17%)	Current	12%	138,221	20,621	34,221	684,426	2,541	39,651	48,385	88,035	117,838	weakly dominated	weakly dominated
	Focused	8%	148,803	13,667	41,175	823,508	2,673	47,324	32,152	79,476	126,398	1,154	58
	Universal	7%	155,765	11,740	43,102	862,040	2,863	49,604	27,654	77,258	128,616	1,183	59
	Highly focused	22%	32,175	15,266	10,635	212,703	504	8,096	31,856	39,952	46,671		
Kenya (7%)	Current	13%	63,584	9,041	16,860	337,200	1,513	13,610	18,891	32,501	54,122	weakly dominated	weakly dominated
	Focused	10%	57,366	7,053	18,848	376,953	1,249	14,785	14,751	29,536	57,087	814	41
	Universal	6%	65,658	4,350	21,551	431,016	1,562	17,055	9,121	26,175	60,448	840	42
	Highly focused	21%	10,923	5,026	3,247	64,937	326	2,921	10,522	13,444	14,310		
Haiti (3%)	Current	17%	14,635	4,014	4,259	85,178	522	3,926	8,408	12,334	15,420	weakly dominated	weakly dominated
	Focused	11%	18,731	2,705	5,568	111,357	638	5,089	5,674	10,763	16,992	934	47
	Universal	8%	21,646	1,838	6,434	128,689	771	5,915	3,864	9,778	17,976	953	48
·	Highly focused	23%	577	303	214	4,284	231	370	638	1,008	738		
Viet Nam (0.1%)	Focused	11%	1,020	139	378	7,565	448	694	292	987	759	1,977	99
viet ivalli (U.170)	Current	15%	932	188	328	6,569	531	744	397	1,141	605	dominated	dominated
	Universal	6%	1,168	84	433	8,663	665	947	177	1,123	622	4,601	230

¹ as compared to no PMTCT interventions

² based on PMTCT cost only, does not include paediatric treatment cost

Supplementary table 2. Virtual country scenario

ulation: 50% reside in high HIV burden a portion of HIV-positive women reside in TCT services: ANC coverage 75%, HIV tes cost: same as 4 country-based case scen prevalence positive women in high burden area testing cost diatric treatment cost (annual)	n high burden area: 70% sting coverage 74% among all pregnant women, ART coverage among HIV-infected pregnant women 67%
CCT services: ANC coverage 75%, HIV test cost: same as 4 country-based case scene prevalence positive women in high burden area testing cost	sting coverage 74% among all pregnant women, ART coverage among HIV-infected pregnant women 67% enarios 0.0005% - 20% 50% - 90% 1 US\$ - 6 US\$/test
cost: same as 4 country-based case scel prevalence positive women in high burden area testing cost	enarios 0.0005% - 20% 50% - 90% 1 US\$ - 6 US\$/test
prevalence positive women in high burden area testing cost	0.0005% - 20% 50% - 90% 1 US\$ - 6 US\$/test
positive women in high burden area testing cost	50% - 90% 1 US\$ - 6 US\$/test
testing cost	1 US\$ - 6 US\$/test
•	• • •
diatric treatment cost (annual)	300 US\$ - 1000 US\$/person
Subnational area	
h HIV burden Low burden	
	Current PMTCT service coverage
	Best PMTCT coverage (ANC coverage 95%, HIV testing among ANC attendees 95%, ART coverage among those tested positive 95%)
	Low PMTCT coverage (Current ANC coverage, HIV testing among ANC attendees 20%, ART coverage among those tested positive 95%)
	h HIV burden Low burden